The global stuttering therapeutics market, valued at USD 43 million in 2023, is on track for substantial growth, expected to expand at a CAGR of 14% from 2023 to 2033. By the end of this forecast period, the market is anticipated to reach a value of approximately USS 159.41 million. This growth follows a historical CAGR of 11% from 2018 to 2022, reflecting a steady rise in the demand for effective treatments.
The stuttering therapeutics market includes a range of medications, therapies, and devices developed to treat stuttering—a speech disorder marked by involuntary repetitions, prolongations, and pauses in speech. As awareness of speech disorders increases, healthcare providers and pharmaceutical companies are focusing on innovative therapeutic options that enhance the quality of life for those affected.
With the emergence of advanced treatment modalities and supportive research initiatives, the stuttering therapeutics market is expected to witness transformative advancements, offering patients new avenues for managing this complex speech disorder.
The global stuttering therapeutics market is expected to grow significantly in the coming years, driven by an increasing awareness of the disorder, a growing patient population, and advances in research and development of new treatments.
Currently, there are several medications available for stuttering, including antipsychotic drugs, antidepressants, and anticonvulsants. However, these medications are not specifically approved by the FDA for the treatment of stuttering and may have significant side effects.
Speech therapy is the most common and effective treatment for stuttering, and it involves teaching patients techniques to improve fluency and communication. Other therapies, such as cognitive-behavioral therapy and hypnotherapy, have also been used with some success.
There are also several devices available that can assist with stuttering, including electronic fluency devices, which use altered auditory feedback to help improve speech fluency.
Market Competition
Key players in the market include companies such as Competition Deep Dive, Auspex Pharmaceuticals, Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, AstraZeneca, AbbVie Inc. along with healthcare providers and technology companies among other global players.
- In October 2022, Vivera announced that the US Patent and Trademark Office (USPTO) has granted a US patent allowance for the Company’s method and device for evaluating and providing feedback on Speech Fluency. Stuttering, a speech disorder that causes disfluencies in speech, affects 70 million individuals across the globe. Although there are treatments available, it can be challenging for clinicians to assess stuttering accurately, as its severity may fluctuate over time and in different situations.
Recognizing the need for a more precise evaluation of patient speech disfluencies in real-world settings, Vivera developed a stuttering severity assessment device. This innovative device allows for continuous monitoring of a patient’s stuttering, enabling a more accurate assessment and providing feedback to the patient in real-time. By gathering personalized patient data, clinicians can monitor the therapeutic effects of treatment and adjust therapy accordingly.
Key Companies Profiled
Competition Deep Dive, Auspex Pharmaceuticals, Inc., GlaxoSmithKline plc., Johnson & Johnson Services, Merck & Co., Inc., Pfizer Inc., Siemens Healthcare GmbH, Novartis AG, AstraZeneca, AbbVie Inc.
Key Segments Profiled in the Stuttering Therapeutics Industry Survey
Treatment:
- Speech therapy
- Stuttering Devices
- Cognitive behavioural therapy
- Parent-child interaction
- Drug therapy
Type:
- Developmental stuttering
- Neurogenic stuttering
End User:
- Hospitals
- Specialty Clinics
- Homecare
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
Author By:
Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.
Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.
Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube